Shots:

• The P-IIb TRANSLATE-TIMI 70 study evaluates the efficacy, safety, tolerability & PK of vupanorsen vs PBO in 286 patients aged ≥ 40yrs. with dyslipidemia with elevated non-HDL-C & TG who receives a stable dose of a statin. The results will be present in 2022
• The study met its 1EPs & 2EPs i.e., the therapy showed a reduction in non-HDL-C, TG & ANGPTL3 at all doses @24wks., no patients had a confirmed platelet count abnormality or a confirmed reduction in an estimated GFR & no SAEs were observed
• Vupanorsen is an antisense therapy that was discovered by Ionis & developed by Pfizer. Additionally, Pfizer continues to review the results to identify the next steps for future development

Click here to­ read full press release | Ref: Ionis | Image: The Wall Street Journal